Ikarovec presents key PoC data on the wAMD and GA programmes at the ARVO and ASGCT conferences in 2023

The Ikarovec team presented key proof-of-concept data identifying lead gene therapy candidates for both the neovascular age-related macular degeneration and geographic atrophy programmes at the Association for Research in Vision and Ophthalmology (ARVO) conference in New Orleans (23-27 April 2023) and the American Society of Gene and Cell Therapy (ASGCT) in Los Angeles (17-20 May 2023). Based on these exciting data the company is planning to transition these gene therapy candidates into further development in H2 2023.